Sopherion Therapeutics
closedSopherion has the US and Canadian rights to this liposomal nanotechnology that targets the tumor vasculature.
Launch date
Employees
Market cap
-
Enterprise valuation
€171—256m (Dealroom.co estimates Sep 2004.)
New Brunswick New Jersey (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
$26.0m | Series A | ||
$47.0m | Series B | ||
$35.0m | Late VC | ||
$55.0m | Series C | ||
Total Funding | €148m |
Related Content
Recent News about Sopherion Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.